FDA Class II Recall: Teva Pharmaceuticals' Warfarin Sodium Affected by Cardinal Healthcare Storage Deviations
Teva Pharmaceuticals USA, Inc.'s Warfarin Sodium Tablets faced a Class II recall initiated by CARDINAL HEALTHCARE due to CGMP deviations involving temperature excursions during storage. This event, now terminated, underscores critical supply chain vulnerabilities for procurement and regulatory teams, demanding rigorous oversight of distributor storage protocols for sensitive pharmaceuticals.
FDA Class II Recall for Warfarin Sodium Due to CGMP Storage Deviations
The U.S. Food and Drug Administration (FDA) has classified a Class II recall, D-0201-2024, for Warfarin Sodium Tablets, USP, 5 mg, manufactured for Teva Pharmaceuticals USA, Inc. The recall was initiated by CARDINAL HEALTHCARE, based in Dublin, OH, on January 26, 2022, and officially reported on January 3, 2024, before being terminated on September 29, 2024. The core issue identified was a Current Good Manufacturing Practices (CGMP) deviation: products from Batch 2323041 were exposed to temperatures outside their labeled storage conditions. This incident, though involving a single unit of the 100-tablet bottle (NDC: 0093-1721-01), highlights a critical vulnerability in the pharmaceutical supply chain. For procurement directors and supply chain VPs, this event signals the imperative to re-evaluate the environmental control protocols of all distribution partners. Any deviation from labeled storage conditions for a critical anticoagulant like Warfarin Sodium can compromise its stability, efficacy, and ultimately, patient safety. Ensuring that distributors adhere strictly to CGMP guidelines, particularly concerning temperature-sensitive products, is not merely a regulatory checkbox but a fundamental requirement for maintaining product quality and avoiding costly recalls and reputational damage.
Supply Chain Exposure and Product Integrity for Warfarin Sodium
Warfarin Sodium is a widely prescribed anticoagulant, essential for preventing and treating thromboembolic events. Its efficacy is directly tied to its chemical stability, which can be significantly impacted by temperature fluctuations. The Class II classification indicates that exposure to these conditions may cause temporary or medically reversible adverse health consequences, or that the probability of serious adverse health consequences is remote. However, for a drug with a narrow therapeutic index like Warfarin, even minor potency changes due to temperature excursions can have serious clinical implications for patients. This incident, while specific to one batch and a limited quantity, underscores broader supply chain risks. Procurement teams sourcing Warfarin Sodium or other temperature-sensitive APIs and finished drug products must understand that the manufacturer's quality control extends beyond their facility gates. The integrity of the product relies heavily on the storage and handling practices of every entity in the distribution network. Regulatory affairs heads need to ensure that quality agreements with distributors explicitly detail environmental monitoring requirements and robust deviation management procedures, holding partners accountable for maintaining product specifications from manufacturing to patient delivery.
Distributor's Operational Risk: Cardinal Healthcare's Compliance History
CARDINAL HEALTHCARE, the recalling firm, is a major player in pharmaceutical distribution. The recall originating from their Dublin, OH facility (7200 Cardinal Pl W, 43017-1094) due to temperature excursions points to potential systemic issues in their storage and handling operations. This is not an isolated incident for the broader Cardinal Health entity; a parallel event saw Cardinal Health Inc. face an FDA Class II recall for XIGDUO XR due to similar storage temperature excursions, as published on June 16, 2026. This pattern raises concerns about the consistency and robustness of their environmental control systems across different product lines and distribution centers. For supply chain VPs and business development executives, this recurring issue with a key distributor like Cardinal Healthcare presents a tangible risk. Relying on partners with documented compliance challenges, especially regarding critical storage conditions, can lead to repeated product quality issues, regulatory scrutiny, and potential market withdrawals. It necessitates a thorough re-evaluation of vendor qualification processes, demanding comprehensive audits of their environmental monitoring systems, staff training on CGMP, and documented corrective and preventive actions (CAPA) to ensure such deviations are not merely addressed but systematically prevented across all distributed products.
Manufacturer's Oversight and Brand Protection: Teva Pharmaceuticals USA, Inc.
While CARDINAL HEALTHCARE initiated the recall, Teva Pharmaceuticals USA, Inc. bears the ultimate responsibility as the manufacturer of record for the Warfarin Sodium Tablets (ANDA040616). Any quality issue, regardless of where it occurs in the supply chain, inevitably impacts the manufacturer's brand reputation and regulatory standing. The product's National Drug Codes (NDCs) such as 0093-1712, 0093-1713, and 0093-1721 are directly linked to Teva, making their brand synonymous with the product's quality. Regulatory affairs heads at Teva and other pharmaceutical manufacturers must recognize that their quality management systems must extend beyond their own manufacturing sites to encompass the entire distribution network. This includes rigorous qualification of third-party logistics (3PL) providers and distributors, regular audits, and robust contractual agreements that mandate adherence to specific storage conditions and reporting protocols. Proactive oversight is crucial to protect brand integrity, ensure patient safety, and mitigate the commercial impact of downstream compliance failures, even when the immediate cause lies with a distribution partner.
Remediation and Future Compliance Expectations for Distribution Networks
The termination of recall D-0201-2024 on September 29, 2024, indicates that the FDA is satisfied with the corrective actions taken by CARDINAL HEALTHCARE for this specific batch of Warfarin Sodium Tablets. While this particular event is closed, the underlying issue of temperature excursions during storage, especially given Cardinal Health Inc.'s prior similar recall for XIGDUO XR, suggests a need for ongoing vigilance and systemic improvements within distribution networks. The voluntary, firm-initiated nature of the recall indicates internal quality systems identified the problem, which is a positive sign, but recurrence remains a concern. For senior decision-makers, this event serves as a critical reminder that compliance is a continuous process. Procurement directors should insist on detailed CAPA documentation from all distribution partners, focusing on the root causes of temperature deviations and the effectiveness of implemented controls. Supply chain VPs must integrate real-time environmental monitoring and alert systems across their distribution channels. Regulatory affairs heads should consider enhanced audit frequencies for distributors handling temperature-sensitive products, ensuring that lessons learned from such recalls translate into robust, preventative measures across the entire pharmaceutical supply chain to safeguard product quality and market access.